Mediation is set to become a more prominent feature of New Zealand’s legal landscape, including in intellectual property disputes. Mediation will be strongly encouraged in cases placed on the new, fast-track Commercial List in the High Court of New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 January 2026 are set out below…
Seqirus, Inc. opposed Translate Bio, Inc.’s patent application (AU2020202755) concerning the in vivo delivery of mRNA for augmenting proteins and enzymes in genetic diseases. The invention’s contribution lay in specific liposome-forming lipid…
This decision concerns the apportionment of costs arising from the substantive decision in Miele & Cie KG v Bruckbauer [2025] FCA 537 (27 May 2025) (Substantive Decision). Justice Rofe considered the appropriate apportionment of costs…
Pearce IP and Chantal Savage, have been ranked in Australia for Intellectual Property in the Legal 500 Asia Pacific 2026 Rankings. Legal 500 rankings take in a broad scope of client and law firm information, combining qualitative and quantitative data to create a strategic compass for clients who are searching for the best legal advisers for their type of work.
Justice Jackman has confirmed that, in the context of a preliminary discovery application, where a prospective applicant vacates a hearing date and the prospective respondent has incurred costs in preparing for the vacated hearing…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the prior three weeks ending 9 January 2026 are set out below…
Newron Pharmaceuticals and Zambon have succeeded in their preliminary discovery application against Arrotex Pharmaceuticals in the Federal Court of Australia. Newron and Zambon sought production of documents from Arrotex, for the purpose of…
Justice Rofe has handed down an interlocutory judgment dismissing Zoetis Australia Pty Ltd’s (Zoetis) application for summary dismissal of Scidera, Inc.’s (Scidera) patent infringement claims. The decision addresses a novel question of Australian patent law…
In a lengthy 1300+ paragraph judgment, Justice Downes has handed victory to Orica, finding that Orica achieved “almost complete success” in its infringement case regarding three of the four patents in suit…
Pearce IP’s CEO and Founder, Naomi Pearce, has been recognised in the IAM Strategy 300 Global Leaders 2026 – the annual showcase of the world’s leading IP strategists. This latest honour follows her previous inclusions in 2020, 2021 and 2022.
Pearce IP’s Head of Litigation (NZ), Paul Johns, explores the usefulness of Swiss-type claims in New Zealand patents, including comparisons of key points of law and practice in other countries. He discusses the particular requirements for Swiss claims under New Zealand practice, contrasts the law and practice…
No Relief for EIS – Federal Court Invalidates Pressure Wave Massager Patent and Dismisses Infringement Claims Against LELO
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 December 2025 are set out below…
Justice Burley of the Federal Court has delivered judgment in proceedings between CPC Patent Technologies Pty Ltd (CPC) and Apple Pty Limited and Apple Inc (collectively, Apple), concerning alleged patent infringement by Apple’s biometric security…
Full Court Resurrects Computer-Implemented Inventions from the Patent Graveyard. In a significant development in the long-running Aristocrat patent saga, the Full Court of the Federal Court has allowed Aristocrat Technologies Australia…
Swiss-style (or Swiss-type) patent claims have been routinely sought and granted in New Zealand for many years. However, the New Zealand courts are yet to determine the question of what conduct will infringe such a claim.
Sally Paterson and Paul Johns discuss and compare various intellectual property laws in New Zealand that provide protection for three-dimensional designs and shapes.
On 5 December 2025, Justice Burley of the Federal Court of Australia granted Janssen a preliminary injunction to restrain Juno Pharmaceuticals from launching generic versions of paliperidone palmitate long acting injectables (LAIs)…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 December 2025 are set out below…
Pearce IP’s CEO, Naomi Pearce, speaks with our Heads of Litigation for Australia and New Zealand about the practice of “skinny labelling” of generic drugs. They discuss whether a “skinny label” approach will assist in avoiding patent infringement of method of treatment or Swiss-style claims in Australia and New Zealand respectively.
Pearce IP and Leaders Recognised in Chambers Asia-Pacific 2026 Rankings for Third Consecutive Year
This article is the second in a series that explores the history of Swiss-style (Swiss-type) claims in New Zealand, the relevant law and policy considerations, and the likely judicial approach to the question of infringement.
High Court Draws Clear Line Between Trade Mark Infringement and Misleading & Deceptive Conduct in Bed Bath N’ Table Case
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
